Unknown

Dataset Information

0

Efficient Presentation of Multiple Endogenous Epitopes to Both CD4+ and CD8+ Diabetogenic T Cells for Tolerance.


ABSTRACT: Antigen-specific immunotherapy of type 1 diabetes, typically via delivery of a single native ? cell antigen, has had little clinical benefit to date. With increasing evidence that diabetogenic T cells react against multiple ? cell antigens, including previously unappreciated neo-antigens that can be emulated by mimotopes, a shift from protein- to epitope-based therapy is warranted. To this end, we aimed to achieve efficient co-presentation of multiple major epitopes targeting both CD4+ and CD8+ diabetogenic T cells. We have compared native epitopes versus mimotopes as well as various targeting signals in an effort to optimize recognition by both types of T cells in vitro. Optimal engagement of all T cells was achieved with segregation of CD8 and CD4 epitopes, the latter containing mimotopes and driven by endosome-targeting signals, after delivery into either dendritic or stromal cells. The CD4+ T cell responses elicited by the endogenously delivered epitopes were comparable with high concentrations of soluble peptide and included functional regulatory T cells. This work has important implications for the improvement of antigen-specific therapies using an epitope-based approach to restore tolerance in type 1 diabetes and in a variety of other diseases requiring concomitant targeting of CD4+ and CD8+ T cells.

SUBMITTER: Dastagir SR 

PROVIDER: S-EPMC5363322 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficient Presentation of Multiple Endogenous Epitopes to Both CD4<sup>+</sup> and CD8<sup>+</sup> Diabetogenic T Cells for Tolerance.

Dastagir Shamael R SR   Postigo-Fernandez Jorge J   Xu Chunliang C   Stoeckle James H JH   Firdessa-Fite Rebuma R   Creusot Rémi J RJ  

Molecular therapy. Methods & clinical development 20161224


Antigen-specific immunotherapy of type 1 diabetes, typically via delivery of a single native β cell antigen, has had little clinical benefit to date. With increasing evidence that diabetogenic T cells react against multiple β cell antigens, including previously unappreciated neo-antigens that can be emulated by mimotopes, a shift from protein- to epitope-based therapy is warranted. To this end, we aimed to achieve efficient co-presentation of multiple major epitopes targeting both CD4<sup>+</sup  ...[more]

Similar Datasets

| S-EPMC4203508 | biostudies-literature
| S-EPMC5778106 | biostudies-literature
| S-EPMC11018974 | biostudies-literature
| S-EPMC7590512 | biostudies-literature
| S-EPMC7489334 | biostudies-literature
| S-EPMC9244519 | biostudies-literature
| S-EPMC6243131 | biostudies-literature
| S-EPMC10682379 | biostudies-literature
| S-EPMC5319715 | biostudies-literature
| S-EPMC7268777 | biostudies-literature